Comment from Anonymous

Re: Pharmacokinetic and Biodistribution Considerations for mFLUSIVA (mRNA-1010) — Docket No. FDA‑2026‑N‑4162 To the Members of the Vaccines and Related Biological Products Advisory Committee (VRBPAC): We submit these scientific considerations regarding the upcoming review of mFLUSIVA (mRNA‑1010) for entry into the official administrative record. This brief provides an objective, literature-backed framework demonstrating why mRNA-lipid nanoparticle (LNP) platforms represent unique biological profiles that cannot be assumed equivalent to traditional inactivated influenza active controls (e.g., Fluarix/Influsplit) or to prior mRNA sequences based on macro-level clinical endpoints alone. Key Pharmacological Considerations 1. Modality-Specific Exposure Pathways Traditional egg‑based vaccines deliver pre‑formed protein antigens processed locally and largely confined to the injection site. Conversely, mRNA‑LNPs function as transient nucleic acid delivery systems whose safety and biological fate depend on the in vivo kinetics of the LNP vector itself (including systemic circulation, cellular tropism, and clearance pathways)—introducing complex physiological exposure pathways entirely lacked by traditional flu vaccines. 2. Microstructural Drivers of Biodistribution The peer‑reviewed literature establishes that the biodistribution of an mRNA-LNP product is highly sensitive to its precise molecular composition. Minor modifications to LNP lipid ratios (Paunovska et al., 2018), surface protein corona formation/ApoE binding (Sebastiani et al., 2021), or mRNA payload properties (length, modifications, secondary structure) can materially alter organ tropism and cellular uptake. Altering the mRNA sequence changes the biological journey of the entity, introducing distinct safety and tissue-interaction variables lacked by traditional flu vaccines. Bridging data from prior mRNA formulations to mFLUSIVA risks overlooking these microstructural drivers. 3. Resolution Limitations of Whole-Tissue Homogenates Standard preclinical assessments frequently rely on whole-tissue homogenate measurements, which average analyte signals across an entire organ mass (Bahl et al., 2017). This mathematical averaging can obscure tissue "hotspots" that occupy a minute fraction of tissue weight yet possess unique toxicological relevance. To fully map biological fate, macroscopic assays benefit from high-resolution cellular and intracellular tracking (Halma et al., 2023). Human pharmacokinetic data demonstrate that intact mRNA-LNPs routinely enter and recirculate within human blood circulation, remaining quantifiable for up to two weeks post-injection (Lee et al., 2025)—a pharmacokinetic profile and prolonged systemic exposure completely lacked by traditional flu vaccines. Spatially resolved methods (vascular‑fractionation, RNAscope, imaging mass spectrometry) are established approaches to distinguish localized signals from true parenchymal transfection (Sago et al., 2018). Conclusion for the Record A robust body of peer-reviewed literature confirms that an mRNA-LNP therapeutic behaves as a unique biological entity whose systemic journey is governed by its specific molecular, structural, and payload composition. To ensure the public administrative record aligns with modern clinical pharmacology, the evaluation of this candidate is optimized by considering the limitations of platform-level bridging, the utility of using spatially resolved methods alongside traditional whole-tissue homogenates, and the impact of baseline inflammatory status on LNP reactogenicity—all of which encompass safety and pharmacokinetic variables fundamentally lacked by traditional flu vaccines. Respectfully, Anonymous References Bahl, K., et al. (2017). Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Molecular Therapy, 25(6), 1316–1327. Halma, M. T., et al. (2023). Deciphering the biological fate of mRNA-LNP-based therapeutics: A perspective from tissue to intracellular distribution. Advanced Drug Delivery Reviews, 199, 114954. Lee, W. S., et al. (2025). Blood distribution of SARS-CoV-2 lipid nanoparticle mRNA vaccine in humans. ACS Nano, 19(3), 1842–1851. Parhiz, H., et al. (2022). Added to pre-existing inflammation, mRNA–lipid nanoparticles induce inflammation exacerbation (IE). Journal of Controlled Release, 344, 50–61. Paunovska, K., et al. (2018). Analyzing 2000 in vivo drug delivery data points reveals cholesterol structure impacts nanoparticle delivery. ACS Nano, 12(8), 8341–8349. Sago, et al. (2018). High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing. PNAS, 115(42), E9944–E9952. Sebastiani, F., et al. (2021). Apolipoprotein E binding drives structural and compositional rearrangement of mRNA-containing lipid nanoparticles. ACS Nano, 15(4), 6709–6722.